These results suggest that reducing the level of mutant FGFR3, a common outcome of both tubacin and tubastatin A treatment and loss of HDAC6, may contribute to the tumor suppression observed, but that the additional activities of tubacin with respect to inhibiting MYC and cyclin D1 and inducing DNA damage signaling may contribute to its superior ability to kill tumor cells and suppress tumor growth. The gene discussed is CCND1; the disease is neoplasm.